Cargando…

Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study

Background: Oxidative stress plays an important role in weight gain induced by antipsychotics in schizophrenia (SCZ). However, little is known about how antioxidant enzymes are involved in weight gain caused by risperidone monotherapy in antipsychotics-naïve first-episode (ANFE) patients with SCZ. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Haixia, Yu, Rui, Gao, Yanan, Li, Xirong, Guan, Xiaoni, Thomas, Kosten, Xiu, Meihong, Zhang, Xiangyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881063/ https://www.ncbi.nlm.nih.gov/pubmed/34544343 http://dx.doi.org/10.2174/1570159X19666210920090547

Ejemplares similares

The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study
por: Liu, Jiahong, et al.
Publicado: (2021)

Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study
por: Liu, Haixia, et al.
Publicado: (2022)

Superoxide Dismutase, BDNF, and Cognitive Improvement in Drug-Naive First-Episode Patients With Schizophrenia: A 12-Week Longitudinal Study
por: Wu, Zhiwei, et al.
Publicado: (2021)

Genetic polymorphisms of BDNF on cognitive functions in drug-naive first episode patients with schizophrenia
por: Su, Xiuru, et al.
Publicado: (2021)

Association between Changes in Total Antioxidant Levels and Clinical Symptom Improvement in Patients with Antipsychotic-Naïve First-Episode Schizophrenia after 3 Months of Risperidone Monotherapy
por: Wang, Keqiang, et al.
Publicado: (2022)

Plasma Lysophosphatidylcholine and Lysophosphatidylethanolamine Levels Were Associated With the Therapeutic Response to Olanzapine in Female Antipsychotics-naïve First-episode Patients With Schizophrenia
por: Liu, Jiahong, et al.
Publicado: (2021)

Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study
por: Lang, Xiaoe, et al.
Publicado: (2023)

Obesity, antioxidants and negative symptom improvement in first-episode schizophrenia patients treated with risperidone
por: Gao, Zhiyong, et al.
Publicado: (2023)

Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study
por: Guan, Xiaoni, et al.
Publicado: (2022)

Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia
por: Qiu, Yuying, et al.
Publicado: (2023)

N-Acetylaspartate Reduction in the Medial Prefrontal Cortex Following 8 weeks of Risperidone Treatment in First-Episode Drug-Naïve Schizophrenia Patients
por: Zong, Xiaofen, et al.
Publicado: (2015)

Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients
por: Birur, Badari, et al.
Publicado: (2020)

Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study
por: Sahni, Sukhtej, et al.
Publicado: (2016)

Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study
por: Chen, Xiaofang, et al.
Publicado: (2023)

Effects of Risperidone on Cytokine Profile in Drug-Naïve First-Episode Psychosis
por: Noto, Cristiano, et al.
Publicado: (2015)

Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients
por: Lin, Chen, et al.
Publicado: (2021)

Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
por: Song, Xueqin, et al.
Publicado: (2014)

Association of telomere length and mitochondrial DNA copy number with risperidone treatment response in first-episode antipsychotic-naïve schizophrenia
por: Li, Zongchang, et al.
Publicado: (2015)

Striatum-related spontaneous coactivation patterns predict treatment response on positive symptoms of drug-naive first-episode schizophrenia with risperidone monotherapy
por: Zong, Xiaofen, et al.
Publicado: (2023)

Glucose metabolism, hippocampal subfields and cognition in first-episode and never-treated schizophrenia
por: Xiu, Meihong, et al.
Publicado: (2023)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

RISPERIDONE IN SCHIZOPHRENIA
por: Kumar, P.N. Suresh
Publicado: (1999)

Sex difference in association of symptoms and white matter deficits in first-episode and drug-naive schizophrenia
por: Lang, Xiao-E, et al.
Publicado: (2018)

Reduced learning bias towards the reward context in medication-naive first-episode schizophrenia patients
por: Cheng, Xiaoyan, et al.
Publicado: (2022)

Tardive Dyskinesia Following Low-Dose Risperidone
por: Rokon, Ahmad E, et al.
Publicado: (2022)

Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal fMRI Study
por: Hu, Mao-Lin, et al.
Publicado: (2016)

C677T Polymorphism in the MTHFR Gene Is Associated With Risperidone-Induced Weight Gain in Schizophrenia
por: Liao, Jingping, et al.
Publicado: (2020)

The contribution of the cingulate cortex: treating depressive symptoms in first-episode drug naïve schizophrenia
por: Shen, Haoran, et al.
Publicado: (2023)

Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia
por: Wu, Rong-Qin, et al.
Publicado: (2018)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Duggal, Harpreet S., et al.
Publicado: (1999)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Agarwal, A.K., et al.
Publicado: (1998)

A pilot study to examine the association between COX-2 rs5275 polymorphism and the response to repetitive transcranial stimulation in schizophrenia
por: Wang, Pingping, et al.
Publicado: (2023)

A double-blind randomized trial between risperidone and haloperidol in drug-naive patients with paranoid schizophrenia
por: Sagar, K.J. Vijay, et al.
Publicado: (2005)

Risk factors for medication-induced amenorrhea in first-episode female Chinese patients with schizophrenia treated with risperidone
por: Chen, Haizhi, et al.
Publicado: (2013)

Randomized, double‐blind, 6‐week non‐inferiority study of lurasidone and risperidone for the treatment of schizophrenia
por: Feng, Yuan, et al.
Publicado: (2020)

Structural abnormalities of cingulate cortex in patients with first‐episode drug‐naïve schizophrenia comorbid with depressive symptoms
por: Wei, Gao‐Xia, et al.
Publicado: (2020)

Abnormalities of Electroencephalography Microstates in Drug-Naïve, First-Episode Schizophrenia
por: Sun, Qiaoling, et al.
Publicado: (2022)

Effect of Repetitive Transcranial Magnetic Stimulation in Inducing Weight Loss in Patients with Chronic Schizophrenia: A Randomized, Double-Blind Controlled 4-Week Study
por: Su, Xiuru, et al.
Publicado: (2023)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

COMPARATIVE EFFICACY OF CENTBUTINDOLE & RISPERIDONE IN SCHIZOPHRENIA
por: Chandra, R., et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_ovq25b7nn1ucaf1oie30c6f913